Lead Product(s): AXO-Lenti-PD
Therapeutic Area: Neurology Product Name: OXB-102
Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Axovant Gene Therapies
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 31, 2020
Oxford Biomedica will manufacture GMP batches for Axovant to support the ongoing and future clinical development of AXO-Lenti-PD, a clinical-stage gene therapy product to treat moderate to severe Parkinson’s Disease based on Oxford Biomedica’s LentiVector® platform.